Skip to content

EV / EBITDA at other companies

ALN
Alnylam PharmaceuticalsALNY
52.6×
Royalty Pharma logo
Royalty PharmaRPRX
13.9×+1.7×
Alkermes logo
AlkermesALKS
30.8×+18.8×
Revvity logo
RevvityRVTY
16.7×-2.2×
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
13×-4.8×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
16.4×-5.2×

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Calculated from Arrowhead Research’s reported figures.

Based on the most recent quarter.

The official record: Arrowhead Research’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's EV / EBITDA?
Arrowhead Research (ARWR) reported EV / EBITDA of 27.4× in Q4 2025.
What does EV / EBITDA mean?
What the whole business (debt included) costs relative to its operating cash earnings.
How do you interpret EV / EBITDA?
Lets you compare companies with different leverage and tax positions on a like-for-like basis — the standard multiple in M&A. Lower can mean cheaper, subject to growth and capital intensity.
How does EV / EBITDA compare across companies?
Broadly comparable across non-financial sectors; not used for banks and insurers, where EBITDA is not meaningful.